CVS brings back coverage for Lilly's obesity drug Zepbound - Reuters
CVS brings back coverage for Lilly's obesity drug Zepbound Reuters Foundayo and Zepbound now covered for millions of Americans investor.lilly.com CVS Caremark will cover Lilly’s weight loss drug Zepbound again after patient backlash NBC News CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans CNBC Eli Lilly shares edge higher after CVS expands coverage for Zepbound obesity drug (LLY) Yahoo Finance
YesNo saves this item as an on-site live signal so search users can understand how it connects to prediction markets and incubation topics.
If later reporting creates a clear deadline, official source, or verifiable outcome, the public event can become a tradable Yes/No question.
This item has a verifiable event angle that can be monitored for a Yes/No prediction market.